123 related articles for article (PubMed ID: 21472182)
21. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach.
Fan Y; Lai MH; Sullivan K; Popiolek M; Andree TH; Dollings P; Pausch MH
Bioorg Med Chem Lett; 2008 Nov; 18(21):5789-91. PubMed ID: 18849166
[TBL] [Abstract][Full Text] [Related]
22. Europium-labeled epidermal growth factor and neurotensin: novel probes for receptor-binding studies.
Mazor O; Hillairet de Boisferon M; Lombet A; Gruaz-Guyon A; Gayer B; Skrzydelsky D; Kohen F; Forgez P; Scherz A; Rostene W; Salomon Y
Anal Biochem; 2002 Feb; 301(1):75-81. PubMed ID: 11811969
[TBL] [Abstract][Full Text] [Related]
23. Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management.
Previti S; Desgagné M; Tourwé D; Cavelier F; Sarret P; Ballet S
J Pept Sci; 2023 Jun; 29(6):e3471. PubMed ID: 36539999
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.
Fanelli R; Besserer-Offroy É; René A; Côté J; Tétreault P; Collerette-Tremblay J; Longpré JM; Leduc R; Martinez J; Sarret P; Cavelier F
J Med Chem; 2015 Oct; 58(19):7785-95. PubMed ID: 26348111
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro10) close to the experimentally derived bioactive conformation of NT(8-13).
Bittermann H; Einsiedel J; Hübner H; Gmeiner P
J Med Chem; 2004 Oct; 47(22):5587-90. PubMed ID: 15481995
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.
Lundquist JT; Dix TA
J Med Chem; 1999 Nov; 42(23):4914-8. PubMed ID: 10579853
[TBL] [Abstract][Full Text] [Related]
27. Receptor mediated internalization of neurotensin in transfected Chinese hamster ovary cells.
Hermans E; Octave JN; Maloteaux JM
Biochem Pharmacol; 1994 Jan; 47(1):89-91. PubMed ID: 8311847
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog.
Chartier M; Desgagné M; Sousbie M; Rumsby C; Chevillard L; Théroux L; Haroune L; Côté J; Longpré JM; Boudreault PL; Marsault É; Sarret P
Biomed Pharmacother; 2021 Sep; 141():111861. PubMed ID: 34229249
[TBL] [Abstract][Full Text] [Related]
29. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
[TBL] [Abstract][Full Text] [Related]
30. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice.
Bredeloux P; Costentin J; Dubuc I
Behav Brain Res; 2006 Dec; 175(2):399-407. PubMed ID: 17074405
[TBL] [Abstract][Full Text] [Related]
31. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
32. Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues.
Lundquist JT; Dix TA
Bioorg Med Chem Lett; 1999 Sep; 9(17):2579-82. PubMed ID: 10498212
[TBL] [Abstract][Full Text] [Related]
33. Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13).
Sousbie M; Vivancos M; Brouillette RL; Besserer-Offroy É; Longpré JM; Leduc R; Sarret P; Marsault É
J Med Chem; 2018 Aug; 61(16):7103-7115. PubMed ID: 30035538
[TBL] [Abstract][Full Text] [Related]
34. Neurotensin modulates central muscarinic receptors, an effect which does not involve the high-affinity neurotensin receptor (NTS1).
Schneider PG; López Ordieres MG; Rodríguez de Lores Arnaiz G
Regul Pept; 2010 Aug; 163(1-3):37-42. PubMed ID: 20403392
[TBL] [Abstract][Full Text] [Related]
35. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.
Kokko KP; Hadden MK; Orwig KS; Mazella J; Dix TA
J Med Chem; 2003 Sep; 46(19):4141-8. PubMed ID: 12954066
[TBL] [Abstract][Full Text] [Related]
36. Immunocytochemical identification of low-affinity NTS2 neurotensin receptors in parietal cells of human gastric mucosa.
Schulz S; Röcken C; Ebert MP; Schulz S
J Endocrinol; 2006 Oct; 191(1):121-8. PubMed ID: 17065395
[TBL] [Abstract][Full Text] [Related]
37. Structure-based evolution of subtype-selective neurotensin receptor ligands.
Schaab C; Kling RC; Einsiedel J; Hübner H; Clark T; Seebach D; Gmeiner P
ChemistryOpen; 2014 Oct; 3(5):206-18. PubMed ID: 25478316
[TBL] [Abstract][Full Text] [Related]
38. Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13).
Pang YP; Cusack B; Groshan K; Richelson E
J Biol Chem; 1996 Jun; 271(25):15060-8. PubMed ID: 8663052
[TBL] [Abstract][Full Text] [Related]
39. Neurotensin(8-13) analogs as dual NTS1 and NTS2 receptor ligands with enhanced effects on a mouse model of Parkinson's disease.
Kühl T; Georgieva MG; Hübner H; Lazarova M; Vogel M; Haas B; Peeva MI; Balacheva AA; Bogdanov IP; Milella L; Ponticelli M; Garev T; Faraone I; Detcheva R; Minchev B; Petkova-Kirova P; Tancheva L; Kalfin R; Atanasov AG; Antonov L; Pajpanova TI; Kirilov K; Gastreich M; Gmeiner P; Imhof D; Tzvetkov NT
Eur J Med Chem; 2023 Jun; 254():115386. PubMed ID: 37094450
[TBL] [Abstract][Full Text] [Related]
40. Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2.
Thomas JB; Giddings AM; Wiethe RW; Olepu S; Warner KR; Sarret P; Gendron L; Longpre JM; Zhang Y; Runyon SP; Gilmour BP
J Med Chem; 2014 Sep; 57(17):7472-7. PubMed ID: 25157640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
